Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Aktiespararna's Aktiedagen, Lund 2022
16 slides from Expres2ion Biotech Holding Ab's conference presentation, Sep 26, 2022
Slide 1: Proteins for Life
26th September 2022 Proteins for Life Aktiespararna’s Aktiedagen, Lund Bent U. Frandsen, CEO
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of i
Slide 3: Investment Highlights
Investment Highlights Key player in advanced protein sciences, with deep pipeline of novel vaccines addressing high- value markets High-potential pipeline of key focus within infections diseases and oncology, backed up by strong intellectual property rights Vaccine development platform with track re
Slide 4: Technology Platforms
Technology Platforms ExpreS2ion’s ExpreS2 and AdaptVac’s cVLP platform Particle (VLP) technology AdaptVac’s proprietary virus-like particles (VLP) technology Cell line derived from Drosophila melanogaster securely attaches our proteins to (fruit fly) S2 cells1 the surface of a capsid (outer protein
Slide 5: Deep Pipeline for Value Creation
Deep Pipeline for Value Creation Development Progress Market Pre-clinical DISEASE Project/Target Discovery cGMP / Tox Phase I Phase II Phase III Partner/Funding Potential Pharmacology >€30 billion1 Coronavirus ABNCoV2/SARS-CoV-2cVLP ABNCoV2/SARS-CoV-2 cVLP I / II Ph. III initiated PREVENT-nCoV Progr
Slide 6: Breast Cancer Overview
BREAST CANCER Breast Cancer Overview The ES2B-C001 vaccine can offer significant benefits compared to current treatment options Monoclonal antibodies are the cornerstone of treatment Serious drawbacks exist with these therapies2 for HER2+ breast cancer (>USD 11bn sales)1 • Resistance to monoclonal a
Slide 7: ES2B-C001 Preclinical Proof-of-Concept (I)
BREAST CANCER ES2B-C001 Preclinical Proof-of-Concept (I) ES2B-C001 has demonstrated in vivo proof-of-concept Effectively inhibited tumor development Prevented tumor development with 95% efficiency Tumor growth in FVB mice (HER2-intolerant) ES2B-C001 with adjuvant (n=20) Control (n = 10) Untreated (n
Slide 8: ES2B-C001 Preclinical Proof-of-Concept (II)
BREAST CANCER ES2B-C001 Preclinical Proof-of-Concept (II) ES2B-C001 has demonstrated in vivo proof-of-concept Overcomes trastuzumab-resistance of tumors in vitro Inhibited tumor development in delta16 HER2 tg mice Trastuzumab-sensitive cells Trastuzumab-resistant cells Lung metastasis development in
Slide 9: Progression as Planned
BREAST CANCER Progression as Planned Important steps as ES2B-C001 is moving closer to the planned clinical Phase I trial in 2024 • GMP Manufacturing • Certified GMP (Good Manufacturing Practice) Manufacturers selected and Work Order Statements executed • ExpreS2ion’s processes for manufacturing of m
Slide 10: ABNCoV2 COVID-19 Vaccine
CORONAVIRUS ABNCoV2 COVID-19 Vaccine Bavarian Nordic completed the Phase II study, and initiated the Phase III study Phase II results confirms ABNCoV2 as universal booster Phase III study 1st vaccination on 2nd Sept. 2022 • Evaluation of ABNCoV2 as a booster vaccine in individuals with • 4,000 previ
Slide 11: Partnership with Bavarian Nordic
CORONAVIRUS Partnership with Bavarian Nordic ABNCoV2 is already out-licensed with near-term revenue streams supporting ExpreS2ion AdaptVac receive from Bavarian Nordic ExpreS2ion receive from AdaptVac • EUR 4 million upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to EUR 136 million in
Slide 12: Cash Balance, 2019-2022 Quarterly
FINANCE 1 Cash Balance , 2019-2022 Quarterly SEK millions 180 168 160 142 139 140 125 120 107 108 100 83 80 60 40 30 20 10 13 5 3 5 6 0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 1 For Q4 2021 and Q1 2022, the cash balance combines funds on the Company’s SKAT account (inte
Slide 13: Shareholder Composition
FINANCE Shareholder Composition No. of shareholders has increased to ~14,000, now holding ~37.6 million shares No. of shareholders, No. of shares outstanding including brokers 16.000 40.000.000 14.000 35.000.000 12.000 30.000.000 10.000 25.000.000 8.000 20.000.000 6.000 15.000.000 4.000 10.000.000 2
Slide 14: Peer Comparison Market Valuations
FINANCE Peer Comparison Market Valuations Lower sales estimates and systematic risk taking reducing COVID-19 vaccine valuations Proteins for Life 14
Slide 15: Advancing Towards Key Catalysts
Advancing Towards Key Catalysts 2022 2023 2024 CORONAVIRUS (ABNCoV2) BN Phase II BN Phase II BN Phase III BN Phase III BN initiating BN ready for study initiation study readout study initiation initial trial rolling submission market launch Q3 21 H1 2022 Q3 2022 results towards in H1 2023 (subject t
Slide 16: Thank you for your attention
Thank you for your attention Proteins for Life
ExpreS2ion Biotech Holding — Aktiespararna's Aktiedagen, Lund 2022 on 6ix